Compare M&T Bank Corporation (MTB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs TG Therapeutics Inc — how do they compare? M&T Bank Corporation trades at $217.49 (market cap $31.42B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: M&T Bank Corporation is far larger — about 3.9× TG Therapeutics Inc's market cap, and M&T Bank Corporation pays a 2.76% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and TG Therapeutics Inc for 16 Days on average.
| MTB | TGTX | |
|---|---|---|
Market Cap | $31.42B | $8.16B |
Volume | 1,438,219 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $254.09 | $59.06 |
52-Week Low | $178.63 | $26.94 |
Typical Hold Time | 100 Days | 16 Days |
Enterprise Value | $47.77B | $8.37B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $217.56, up 0.44% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The stock shows strong fundamentals with a P/E of 11.52, net income margin of 30.85%, and three consecutive quarterly earnings beats. Recent developments include a new branch opening in Connecticut and a declared $1.50 dividend payable in September 2026.
The outlook is supported by analyst consensus with a $258.92 price target and a 'Buy' rating from 31% of covering analysts. Key risks include negative net cash flow trends and elevated debt levels, while opportunities lie in loan growth and AI-driven efficiency gains highlighted in recent management commentary.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
